Market revenue in 2023 | USD 1,048.4 million |
Market revenue in 2030 | USD 2,261.3 million |
Growth rate | 11.6% (CAGR from 2023 to 2030) |
Largest segment | Pharmaceutical industry |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceutical Industry, Cosmetics And Household Products, Academic Institutes and Research Laboratories, Diagnostics, Chemicals Industry, Food Industry |
Key market players worldwide | Charles River Laboratories International Inc, SGS, Merck KGaA, Eurofins Scientific SE, Abbott Laboratories, Labcorp Holdings Inc, Evotec SE, Thermo Fisher Scientific Inc, Quest Diagnostics Inc, Agilent Technologies Inc, Catalent Inc, Danaher Corp, Bio-Rad Laboratories Inc |
Pharmaceutical industry was the largest segment with a revenue share of 43.54% in 2023. Horizon Databook has segmented the China in-vitro toxicology testing market based on pharmaceutical industry, cosmetics and household products, academic institutes and research laboratories, diagnostics, chemicals industry, food industry covering the revenue growth of each sub-segment from 2018 to 2030.
As pharmaceutical companies continue to expand their operations in China, competition in in vitro toxicology testing will also increase. There are several factors contributing to this trend. One is the growing demand for in vitro testing services in China's pharmaceutical industry.
Overall, the increasing competition in in-vitro toxicology testing in China is a positive trend for the pharmaceutical industry. It will encourage innovation, drive down costs, and ultimately lead to the development of safer & more effective drugs for patients.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account